5:57 PM
 | 
Nov 28, 2012
 |  BC Extra  |  Company News

Curis gains rights to Genentech cancer compound

Genentech Inc. granted Curis Inc. (NASDAQ:CRIS) exclusive, worldwide rights to develop and commercialize cancer compound CUDC-427 (formerly GDC-0917). Genentech, a unit of Roche (SIX:ROG; OTCQX:RHHBY), will receive $9.5 million up front and is eligible for undisclosed milestones, plus tiered...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >